A B S T R A C T Chronic elevation of circulating parathyroid hormone (PTH) is associated with decreased target cell responsiveness to PTH. To study the subcellular mechanism of this phenomenon we evaluated PTH receptors and adenylate cyclase activity in renal cortical membranes prepared before and after infusion of bovine parathyroid gland extract (PTE) into thyroparathyroidectomized dogs. PTE infusion resulted in a 53% decrease in the number of high-affinity receptors (P < 0.01) associated with a 66% decrease in PTH-stimulated adenylate cyclase (P < 0.01) relative to paired base-line values. Both the equilibrium constant of dissociation (KD) for PTH binding and the concentration of PTH that caused half-maximal stimulation of adenylate cyclase were in the range of 1 to 4 nM, and were unaffected by the PTE infusion. Responsiveness of the renal adenylate cyclase to sodium fluoride was 88% of base-line values. Infusion of the PTE vehicle alone did not affect PTH receptor number or blunt the adenylate cyclase response to PTH.
INTRODUCTION
Hyperparathyroid states in man are often associated with renal and skeletal resistance to the action of exogenous parathyroid hormone (PTH)l (1) (2) (3) (4) (5) . The renal resistance is manifested by blunting of the phosphaturic and urinary cyclic (c)AMP responses to exogenous PTH, and appears to be related to the level of endogenous PTH (2) . A similar state of PTH resistance has been induced by infusion of parathyroid extract (PTE) into normal humans (2) . Although vitamin D deficiency may have additional effects, experimental evidence in calcium-and vitamin D-deficient rats supports the conclusion that elevated levels of PTH per se, and not alterations in extracellular phosphate or calcium concentrations, largely account for the loss of PTH responsiveness (desensitization) in the skeleton (6) and kidney (7) . The subcellular mechanism(s) of this phenomenon has not been clearly defined. Forte et al. (8) and Carnes et al. (9) have demonstrated that the blunted phosphaturic response to PTH in rats with chronic secondary hyperparathyroidism is related to decreased activation of the renal cortical adenylate cyclase. Activation by sodium fluoride (NaF) and other hormones was intact, suggesting a defect at the level of the PTH receptor, or of receptor-adenylate cyclase coupling (8, 9) .
A variety of other peptide hormones, including insulin, glucagon, catecholamines, and gonadotropins are known to down-regulate their own receptors, and thereby attenuate target cell response (10, 11) . Thus, down-regulation of PTH receptors is likely to account for the observed desensitization to PTH. However, loss of hormone receptors cannot be assumed to occur in all states of peptide hormone excess. Exposure of target cells to high levels of hormone in some cases results in altered binding affinity (12) or even an increase in receptor concentration (13) . Furthermore, under some conditions, persistent occupancy of receptors by the desensitizing hormone mimics the appearance of receptor loss (10, 11) . This has in fact been shown to occur in an in vitro model of PTH desensitization (14) .
The hypothesis that increased levels of circulating PTH in vivo result in a decrease in PTH receptor number or affinity has not been tested directly. The recent report that the number of PTH receptors is decreased in chicks with chronic calcium or vitamin D deficiency does provide presumptive evidence that hyperparathyroidism results in a decrease in measured PTH receptors (15) . However, the role of persistent occupancy has not been fully evaluated. We studied a canine model of PTH desensitization to evaluate the effects of increased levels of circulating PTH in vivo on renal PTH receptors and adenylate cyclase. Desensitization was produced by infusion of parathyroid extract (PTE) into thyroparathyroidectomized (TPTX) dogs. The PTH receptor in canine renal cortical plasma membranes has been characterized extensively (16) (17) (18) (19) and, like that of human kidney (20) , displays guanyl nucleotide-sensitive binding of PTH. This property was exploited to evaluate the role of simple residual occupancy in the down-regulation of PTH receptors.
METHODS
Protocol. The objective of the study was to evaluate the effects of increased circulating levels of PTH in vivo on renal PTH receptors and adenylate cyclase. Adult mongrel dogs were studied 1-2 wk after parathyroidectomy. We administered a crude preparation of bovine PTE by continuous intravenous infusion for 20 h (n = 5). Immediately before the infusion a left unilateral nephrectomy was performed for preparation of base-line renal cortical plasma membranes. At the end of the 20-h infusion period, the remaining kidney was removed for preparation of a second set of renal cortical plasma membranes (final). The [1. 2 million U]) were given as intramuscular injections. After recovery from anesthesia the awake animal was placed in a sling for the infusion. Bupivicaine was used for local anesthesia of the incision site and xylazine was given as needed for mild sedation. The experimental group was given an infusion of bovine PTE suspended at 2-5 U/ml in 5% dextrose, 0.2% NaCl, 1 mM acetic acid, 0.1% bovine serum albumin (BSA). The PTH preparations used are described under materials. Dogs 1-4 received a urea-TCA extract of bovine parathyroid gland. Dog 5 was given a Lilly bovine PTE. The PTE was continuously infused by a Sigma motor pump (Sigma Motor, Inc., Middleport, NY) into a forelimb vein at 2.0 ml/kg body wt per h for 20 h. The first two dogs received a bolus of PTH at the beginning of the infusion to ensure rapid attainment of steady-state levels of PTH. Measurement of PTH levels showed this to be unnecessary in the subsequent animals. The average total dose of PTE was 184±18 U/kg. At the end of the 20-h infusion period, the right (final) kidney was removed via a midline incision. Plasma samples for bioactive PTH levels and calcium were obtained every 2 h; plasma phosphate and creatinine every 6 h. Control animals were infused with the vehicle alone. Intravenous calcium gluconate was given to two control animals during the infusion to prevent tetany.
Renal cortical membrane preparation. Highly purified renal cortical plasma membranes were prepared from kidneys immediately after removal by a modification (21) of the method of Fitzpatrick et al. (22) . Membranes were stored in aliquots at -80°C. No loss of receptor or adenylate cyclase activity was seen over a 1-yr period. Membrane protein was assayed by the method of Lowry et al. (23) using BSA as standard. Na+-K+ ATPase, a marker for renal basolateral membranes (24) , was measured to exclude any systematic effect of the PTE infusion, or of unilateral nephrectomy, on the purity of the renal plasma membrane preparation. The specific activity of Na+-K+ ATPase was similar in final membranes of both groups: 436±53 nmol P04/min per mg protein PTE (n = 4); 470±49 control (n = 5). Enrichment of Na+-K+ ATPase activity over homogenate was also similar in final membranes of both groups: 7.4±0.7-fold PTE; 6.9±0.7-fold control.
Measurement of 1251-bPTH binding. Binding assays were done in a final volume of 0.1 ml containing 25 mM Tris/HCl (pH 7.5), 2.0 mM MgCl2. 0.1% BSA, -9,000 cpm (30-150 pg) receptor-purified 125I-bPTH , 0-700 nM unlabeled bPTH , and 250 Ag/ml of plasma mem-branes. Incubations were carried out for 60 min at 30°C. Bound '25I-bPTH was separated by filtration through 0.2-sgm cellulose acetate filters and analyzed as previously described (21) . Binding in the presence of 700 nM bPTH (1-34) was considered nonspecific. Nonspecific and blank binding totaled <2.0% of the added '25I-bPTH , and was routinely subtracted from all binding values. The number and equilibrium dissociation constant of high-affinity binding sites was determined by Scatchard analysis of the displacement binding curves between 0 and 7 nM unlabeled hormone. Putative low-affinity binding sites are not determined by this method.
In vitro PTH exposure. Membranes were incubated in 1-ml aliquots at 30°C for 60 min under the standard conditions used to assay PTH binding, with or without the addition of 24 nM bPTH . Membranes were then washed using the following procedure: the incubation was terminated by dilution with 4 vol of ice-cold incubation medium. Membranes were sedimented at 10,000 g for 10 min at 4°C. The pellet was resuspended in 5 ml of ice-cold 0.25 M sucrose/1.0 mM EDTA/5 mM Tris, pH 7.5 (SET buffer), and resedimented as above. The final pellet was resuspended at 1 mg/ml in SET buffer.
GTP Biologically active PTH. Circulating levels of biologically active PTH were measured in a bioassay using guanyl nucleotide enhancement of canine renal cortical adenylate cyclase in vitro, as previously described by Nissenson et al. (26) . The adenylate cyclase assay was performed as described here, with the addition of 100 MM Gpp(NH)p and 10 Ml plasma. Hypoparathyroid canine plasma served as the vehicle for the PTH standards.
Measurement of Na+-K+ ATPase. Na+-K+ ATPase was measured as previously described (27) , with the following modifications. Renal cortical homogenates and plasma membranes were incubated for 30 min on ice in 0.08% deoxycholate. Fractions were then incubated for 5 min at 370C in 500-Ml volume containing 75 mM Tris-HCl (pH 7.6), 100 mM NaCl, 20 icantly at base line. After the infusion, maximal PTHstimulated adenylate cyclase activity was significantly lower in the PTE group than control (214±30 pmol cAMP/30 min per mg protein, final PTE vs. 673±29 final control, P < 0.001). In contrast, basal, NaF-, and Gpp(NH)p-stimulated activity did not differ significantly in final membranes of the two groups. Fig. 2 presents the adenylate cyclase activity of the final membranes as a percentage of the activity in the paired base-line membranes. The decrease of PTHstimulated adenylate cyclase activity seen after PTE infusion (34±2% of base line) appeared to be a specific effect of the PTE, as no desensitization to PTH was seen in controls (94±18% of base line). In contrast, the effect of PTE infusion on basal, NaF-stimulated, and Gpp(NH)p-stimulated adenylate cyclase activity did not differ from control. NaF-stimulated adenylate cyclase activity was maintained at >88% of base-line activity after PTE infusion, while Gpp(NH)p-stimulated activity was even higher than base line, suggesting that the availability of catalytic cyclase was not limiting PTH responsiveness. These results support the conclusion that PTE infusion induced a state of refractoriness of the renal adenylate cyclase to subsequent PTH stimulation, which is likely to involve a lesion at the level of the PTH receptor.
Studies of 1251-bPTH binding. To test directly the hypothesis that the observed desensitization to PTH involves a decrease in the number of PTH receptors, we evaluated binding of '25I-bPTH to the renal cortical plasma membranes in vitro. A representative pair of binding curves for one PTE-infused dog is shown in Fig. 3 A. Maximum binding fell in the final membranes of all five PTE-infused dogs, to 61±3% of base-line values, but remained at 99±6% of base-line values after infusion of the vehicle alone (Table II) . Scatchard transformation of the binding curves (Table II) showed that a decrease in the number of PTH receptors from 1.89 pmol/mg protein at base line to 0.88 pmol/mg protein after PTE infusion (P < 0.001) accounted for the decreased binding seen in the final membranes of the PTE group. No significant change in receptor number occurred in controls. The equilibrium constant of dissociation (KD) was not altered in either group (Table II) . Fig. 3 (17) (18) (19) . We first established that pretreatment of membranes with GTP reversed the persistent occupancy of receptors that occurred when membranes were exposed to PTH in vitro. Base-line membranes were incubated with a concentration of PTH chosen to reproduce the same magnitude of binding loss seen after PTE infusion. GTP pretreatment completely restored subsequent '25I-bPTH binding in these membranes (Fig. 4) . In contrast, GTP pretreatment did not alter binding in final membranes prepared after exposure to PTE in vivo.
To ensure that the failure of guanyl nucleotide treatment to restore PTH receptors was not due to rapid metabolism of GTP by the membranes, we measured 1251-bPTH binding to desensitized membranes in the presence of the hydrolysis-resistant GTP analogue Gpp(NH)p (Table III) . There was a 60% decrease in PTH binding to all membranes in the presence of Gpp(NH)p, consistent with the reported effect of Gpp(NH)p to decrease binding affinity (16) . Because PTH binding fell proportionately in both base-line and final membranes, binding in the desensitized membranes remained at only 65% of base line. Thus, although Gpp(NH)p clearly affected binding, it failed to equalize the PTH binding of desensitized membranes to that of base line.
In theory, guanyl nucleotide treatment of the final PTE membranes could release persistently bound PTH, thus restoring receptor number, but fail to restore maximal 1251-bPTH GTP pretreatment also failed to restore PTH-stimulated adenylate cyclase activity to base-line values in the desensitized membranes (Fig. 5) . Absolute PTHstimulated activity was increased in all membranes after GTP pretreatment, presumably due to a residual effect of tightly bound GTP on the membranes. However, activity in both the base-line and final membranes was increased proportionately ( (Fig. 5) .
In summary, although GTP pretreatment restored the loss of binding seen after exposure of isolated membranes to PTH in vitro (Fig. 4) , GTP pretreatment reversed neither the receptor loss nor the adenylate cyclase desensitization induced by PTE exposure in vivo (Fig. 5) .
DISCUSSION
The results of this study demonstrate that maintenance of circulating, biologically active PTH at hyperparathyroid levels for 20 h induces a state of renal refractoriness to the hormone that can largely be attributed to a loss of available PTH receptors on renal cortical plasma membranes. Thus, administration of PTE to thyroparathyroidectomized dogs resulted in a 53% loss of renal PTH receptors, which was associated with a 66% decrease in maximal PTH-stimulated adenylate cyclase activity. We suggest that down-regulation of PTH receptors by circulating hormone may play a primary role in the PTH resistance associated with hyperparathyroidism in man.
This hypothesis is consistent with previous data from animal models of secondary hyperparathyroidism. Loreau et Base-line membranes of the PTE group (n = 4) were pretreated with PTH in vitro (E) to achieve the same degree of binding loss seen in the final membranes (in vivo PTH exposure 0). All membrane pairs were then treated with GTP (EN), followed by extensive washing.
Binding is expressed relative to that seen in the paired base-line membranes that had not been exposed to PTH (range 7 to 15% specific binding at base line). Data (33) . In this study, the renal PTH receptors that remained after the 20-h infusion of PTE appeared to be functionally normal. These high-affinity receptors continued to be of a single class (i.e., linear Scatchard plot) with an unaltered affinity for PTH. In addition, they were able to initiate PTH-dependent activation of adenylate cyclase, albeit at a level reduced proportionally with the loss of total receptors.
Components of the adenylate cyclase system beyond the PTH receptor appear to be essentially intact in this model of desensitization. Enzyme activation by NaF and Gpp(NH)p (which activate adenylate cyclase via postreceptor mechanisms) were not different than that seen in controls (34) . The slight decrease in NaF-stimulated adenylate cyclase activity and the increase in Gpp(NH)p-stimulated adenylate cyclase activity that occurred after PTE infusion appeared after the vehicle infusion as well, suggesting that these changes might be related to the compensatory renal hypertrophy known to occur after unilateral nephrectomy (35, 36) . We cannot exclude the possibility that the small (12%) decrease in NaF-stimulated adenylate cyclase activity seen after PTE infusion plays a role in the observed desensitization, but its contribution appears minor.
The results of the present study raise 
